Tonix Pharmaceuticals Holding (TNXP) Common Equity (2010 - 2026)

Tonix Pharmaceuticals Holding's Common Equity history runs 17 years deep, the most recent figure standing at $227.1 million for Q1 2026.

• On a quarterly basis, Common Equity rose 25.91% year-over-year to $227.1 million in Q1 2026; TTM through Mar 2026 was $227.1 million, a 25.91% increase from a year earlier, with the FY2025 full-year figure at $245.2 million, up 75.66% from the prior year.
• Common Equity declined to $227.1 million in Q1 2026 per TNXP's latest filing, from $245.2 million in the prior quarter.
• Across five years, Common Equity topped out at $245.2 million in Q4 2025 and bottomed at $42.1 million in Q2 2024.
• The 5-year median for Common Equity is $168.0 million (2025), against an average of $165.9 million.
• Across the five-year window, Common Equity plunged 70.03% in 2024 and jumped 299.02% in 2025, its largest moves.
• Year by year, Common Equity stood at $207.2 million in 2022, then slumped by 49.07% to $105.5 million in 2023, then soared by 32.25% to $139.6 million in 2024, then jumped by 75.66% to $245.2 million in 2025, then decreased by 7.35% to $227.1 million in 2026.
• Per Business Quant, the three latest TNXP Common Equity figures stand at $227.1 million (Q1 2026), $245.2 million (Q4 2025), and $231.1 million (Q3 2025).